

Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)

This protocol targets insect bat rabies (predominantly North America) in patients with normal immunity at any age, who received rabies vaccine or immunoglobulins (RIG, IGIV).

Patients with insect bat rabies who received vaccine will have accelerated, excessive, and altered immune responses predictive of complications. The immune response is rapid and difficult to control.

| Hospital day (HD) | Risk                                                       | Therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>HD 0</b>       | Cardiac arrest (dysautonomia) in 27% over the first 7 days | <p>Minimize stimulation. Rabies causes extensive sensory and motor denervation over 10 days. The neurological exam is not useful and can stimulate a cardiac arrest. Pupillary exam remains useful.</p> <p>Sedation:<br/> <u>If alert and no dysautonomia:</u><br/> haloperidol (5 mg hourly x 3 doses, the 5 mg daily in divided doses; 0.1 mg/kg hourly x 3, the 0.1 mg/k daily)<br/> <u>If bradycardia or tachyarrhythmia:</u><br/> ketamine (0.5-1.0 mg/kg/h) + 1:1 midazolam. Titrate sedation to prevent dysautonomia with nursing cares.</p> | <p><u>For Diagnosis:</u><br/> Saliva for PCR<br/> Skin biopsy for PCR (or antigen)<br/> Serum for antibody<br/> CSF for antibody<br/> (Corneal impressions NOT recommended)</p> <p>Results of testing can be delayed. It may be necessary to sedate or treat before diagnosis is confirmed. Sedation for 7 days is less dangerous than untreated rabies.</p> <p>EEG or BIS monitoring</p> <p>Rabies mimics include NMDAR autoimmune encephalitis, scorpion sting, elapid snake venom, Guillain Barre syndrome, and orofacial seizures.</p> | <p>Prediction is most accurate based on hospitalization for objective signs (not symptoms). First day =0</p> <p>Vaccination may accelerate immune responses leading to adverse neurological outcomes. RIG or IVIG delays development of CSF antibodies, essential for survival.</p> <p>Sedation is tapered on HD 8 when vagal function ceases. During taper, consider addition of clonidine or dexmedetomidine rather than increases in benzodiazepines or ketamine.<br/> <u>IMPORTANT:</u> vagus nerve function and risk of arrest may persist past HD 7 in patients receiving favipiravir.</p> <p>Haloperidol reduces sensory input and is one of 2 drugs published for palliation of rabies.</p> <p>We DO NOT recommend burst suppression. Ketamine and amantadine are given as neuroprotectants based on quinolinic acid in CSF (excitotoxin) and original use in the successful protocol. Ketamine is anti-nociceptive and avoids altering the pupillary response by opiates. Barbiturates are immunosuppressive and should be avoided. Propofol appears safe but may cause isoelectric EEG in rabies.</p> <p>Ventilate using normal parameters. Rabies patients maintain vascular responsiveness to changes in pCO<sub>2</sub>. Avoid hypocarbia.<br/> Please time tracheostomy between HD 8 and HD 12 to avoid periods of known vasospasm and high risk of dysautonomia in the first 7 hospital days.</p> <p>Antipyretics have no effect in rabies. Ambient temperatures may have major effects on heart rate and blood pressure.</p> |

|                |                                                                                                                        |                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------|------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>HD 0</b>    | Rabies survival is 20% by intention-to-treat                                                                           | <p>Inquire IMMEDIATELY about the possibility of investigational or compassionate use of rabies antivirals, biologics, or gene therapies. These require time for approvals and logistics.</p> <p>Consider administration of interferon-beta.</p>                            | <p><u>Monitoring:</u> Saliva and serum/CSF are tested twice weekly. <i>This is ESSENTIAL for predicting survival/futility and complications</i></p>                                                                                                                                                                        | <p>CSF antibody is necessary for survival. Antibody must be detected by HD 7 (in the absence of experimental therapy) for survival.</p> <p>Chlorhexidine oral care interferes with PCR for rabies virus. Freeze saliva.<br/>CSF should be sent for cells and protein (criteria for futility) and lactate if available.</p> <p>Favipiravir (ebola oral dosing regimen) modifies the clinical course of rabies (less denervation) but its bioavailability in the brain is uncertain. Some countries have favipiravir available (China, Russia, Japan). There are theoretical reasons to administer BOTH IFN-beta and favipiravir together: interferons reduce the purine precursor pool to enhance inhibition by favipiravir.</p> <p>Rabies is inhibited by type I interferons (IFN-alpha and IFN-beta). IFN-alpha can be neurotoxic, but IFN-beta is used to prevent or minimize demyelination in multiple sclerosis. We have only used Avonex 30 mcg IM once weekly. We have anecdotal evidence for a reduction in salivary viral load after IFN-beta. We have not seen adverse effects.</p> <p>Ribavirin is immunosuppressive. It is an inosine monophosphate dehydrogenase (IMPDH) inhibitor, similar to mycophenolate. [see cerebral edema, next]</p> |
| <b>HD 0-16</b> | Cerebral edema (80% of insect bat rabies; <u>likely higher</u> in vaccinated patients). Demyelination during recovery. | <p><u>Prevention:</u><br/>Maintain head of bed elevated 30 degrees;<br/>Serum sodium &gt; 140<br/>Fludrocortisone;<br/>isotonic saline in IVs</p> <p>Consider administration of ribavirin (1000 mg/day in 2 divided doses (adult); 15 mg/kg/day in 2 divided doses x 2</p> | <p>Daily serum sodiums</p> <p>Intracranial pressure monitoring OR daily bedside optic nerve sheath diameter (ONSD) by ultrasound OR transcranial doppler (TCD) resistive index [see appendix for norms].<br/><u>If ONSD or TCD are not available:</u> Twice weekly CT or MRI x 2 weeks (until immune response matures)</p> | <p>Rabies immune response is rapid with prior or concurrent rabies vaccination and predicts complications. Titers are often excessive (&gt;100 IU/ml) [Figure 1]. Bedside or local monitoring (RAPINA cartridges, Platelia II ELISA serology at a local veterinary or medical institute will improve timely care and can be validated at (slower) rabies reference laboratories.</p> <p>Cerebral edema is associated with the immune response. The mechanism is uncertain. There is no evidence for vasogenic edema: the blood-brain-barrier (as evidenced by contrast enhancement) appears to be intact, so the benefit of corticosteroids rests on immune modulation. The cerebral edema appears to last for several weeks.<br/>Dexamethasone (30-40 mg/day adults; 6 mg/kg/d child x 5 days) and IVIG (1 g/kg) appear to slow the immune response when given very but have not shown clear</p>                                                                                                                                                                                                                                                                                                                                                        |

Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)

|  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  |  | <p>wks; round to nearest 200 mg, child x 2 wks ) or mycophenolate mofetil (500 mg twice daily orally, adult x 2 weeks; 600 mg/m<sup>2</sup>/dose twice daily orally, child x 2 weeks)</p> <p>Consider use of a lipid-soluble statin such as simvastatin 80 mg daily to prevent demyelination</p> <p><u>Treatment:</u><br/>External ventricular drain if possible.</p> <p>Avoid diuretics and mannitol.</p> <p>Consider hypernatremia (with prophylaxis against DVTs).</p> <p><b>Consider therapeutic hypothermia.</b></p> <p>Consider JAK inhibitors</p> | <p>Monitor hemoglobin or hematocrit weekly if ribavirin is used.</p> | <p>benefit against later demyelination. [See alternative therapies.]</p> <p>Ribavirin is immunosuppressive and was used in our initial survivor. It can be used pre-emptively. It is an inosine monophosphate dehydrogenase (IMPDH) inhibitor, similar to mycophenolate. Ribavirin and mycophenolate also decrease BH<sub>4</sub> by reducing guanosine pools. Mycophenolate has been studied for multiple sclerosis.</p> <p>Ribavirin accumulates in red blood cells and will lead to hemolysis. Bioavailability in the brain is low.</p> <p>Rabies patients may have cerebral salt-wasting and may progress to diabetes insipidus as a complication. Avoid diuretics and mannitol given the fluid and electrolyte challenges.</p> <p>Statins are immune modulatory and have been studied in multiple sclerosis. Statins increase BH<sub>4</sub> synthesis (decreased in rabies)</p> <p>Insertion of the EVD has been associated with transient PCR positivity of the CSF.</p> <p>Neither MRI nor CT adequately detects early intracranial hypertension. MRI in rabies is not associated with restricted diffusion or contrast enhancement. When these are noted, there has been a complication (arrest) or the diagnosis is not rabies. Bedside testing (ONSD by ultrasound, or TCD ultrasound) detect increases in intracranial pressure associated with the immune response, allowing intervention when serologies lag or transport is risky.</p> <p>Hypothermia should not be considered preventively (when we need an immune response) but makes sense therapeutically to modulate inflammation and the adaptive immune response and is neuroprotective. We only have experience with one patient receiving hypothermia after a cardiac arrest; antibody response was stopped.</p> <p>White matter loss appears during recovery (biphasic) and is consistent with interferonopathy (Aicardi-Goutiere).</p> |
|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)

|                |                                     |                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|----------------|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>HD 0-16</b> | Low risk of nosocomial transmission | Isolation                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                     | <p>There has never been a laboratory-confirmed case of human to human rabies transmission (other than by corneal or solid organ transplantation) during medical care or autopsy. Blood and urine cannot transmit rabies.</p> <p>Patients can be removed from isolation when saliva is negative by PCR on 3 occasions in the presence of neutralizing antibody &gt; 0.5 IU/ml by RFFIT, FAVN or other test for neutralizing antibodies</p>                                                                                                                                                                                                                                                                                 |
| <b>HD 4</b>    | Salt-wasting syndrome on HD 5       | <p>Begin fludrocortisone 100 mcg child or 200 mcg adult or other mineralocorticoid; use lactate or normal saline fluids</p> <p>Minimize vasopressors and diuretics; use fluids to maintain blood pressure</p> <p><u>For hyponatremia</u>, enteric sodium (23%; 1 g in 5 ml water) is more efficacious than 3% IV hypertonic saline</p> | <p>Daily serum sodium and glucose</p> <p>Consider BNP or NT-pro-BNP monitoring</p> <p>Consider serum uric acid and urinary sodium</p> <p>Key test: Saliva for PCR and serum/CSF for neutralizing antibody (HD4)</p> | <p><i>Avoidance of hyponatremia appears to prevent vasospasm in human rabies. [See HD 6-8]</i></p> <p>A physiological dose of hydrocortisone (1X dosing) may be used if no pure mineralocorticoid: 15 mg/day divided Q8-12h in adults; 8 mg/m<sup>2</sup>/day divided Q8h in children. HC risks immunosuppression at higher doses.</p> <p>Central venous pressure appears inaccurate in rabies. Monitoring inferior vena cava collapse by bedside ultrasound is preferred.</p> <p>Rabies is associated with tetrahydrobiopterin (BH<sub>4</sub>) deficiency, that causes adrenaline deficiency as well as nitric oxide (NO) deficiency. Vasopressor agonism is not opposed by NO dilation, leading to profound ileus.</p> |
| <b>HD 4</b>    | Neuroprotection during rabies       | Hypothermia is NOT recommended preventively but should be strongly considered for cerebral edema associated with the immune response (HD0-15).                                                                                                                                                                                         | <p>Daily serum glucose and glucose</p> <p>Urine dipsticks for ketones, daily</p> <p>Begin daily baseline optic nerve sheath diameters by ultrasound (ONSD) or</p>                                                   | <p>This is NOT tight glucose control, rather prevention of catabolism. Reduce insulin for hypoglycemia but maintain some insulin.</p> <p>Complications in rabies are associated with CSF markers of gluconeogenesis and ketogenesis (branched chain amino acids, glycine, acetone, isopropanol). Promotion of anabolism (with adequate caloric intake) appears to improve survival curves by about one week. Insulin may minimize toxic alcohol metabolites and lactic acidosis associated with benzodiazepine sedatives.</p> <p>Amantadine (alone with ketamine and midazolam) were part of the original successful protocol. There is biochemical evidence for high quinolinic acid in CSF</p>                          |

Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)

|               |                                                                        |                                                                                                                                                                                                                 |                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|               |                                                                        | <p>Begin low-dose insulin infusion (0.5 U/h regular insulin in adults; 0.005 U/kg/h in children) and gastric or jejunal feeds.</p> <p>Amantadine, Vitamin C (500 mg) and vitamin B complex are recommended.</p> | transcranial doppler ultrasounds (TCD) – see cerebral edema                                                | <p>during rabies (excitotoxicity). Ketamine, midazolam and amantadine are neuroprotectants.</p> <p>Vitamin C recycles BH<sub>2</sub> to BH<sub>4</sub>. B vitamins may minimize demyelination.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>HD 4</b>   | Thrombosis of cerebral veins or sinuses                                | DVT prophylaxis                                                                                                                                                                                                 |                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>HD 6-8</b> | Generalized intracranial vasospasm leading to coma                     | (fludrocortisone and Na > 140 meq/L)                                                                                                                                                                            | Optional transcranial doppler ultrasound (needs baseline study) on HD 4-8 and HD 12-15                     | <p>Prophylaxis for vasospasm can also be considered using (a) sapropterin (BH<sub>4</sub>, Kuvan (Merck) (5 mg/kg/day), vitamin C (500 mg) and 0.5 g/kg/day of arginine or citrulline, or (b) nimodipine at ½ to 1/3 the standard dose x 14 days. Sapropterin is preferred but often unavailable. Sapropterin may also improve adrenaline synthesis in the infected adrenal gland. Do NOT use sapropterin and nimodipine together.</p> <p>Vasospasm is associated with onset of coma and mild dysautonomia and pupillary changes. This is evident by transcranial doppler ultrasound and lasts about 1 day, then resolves. Vasospasm is followed by a gradual increase in intracranial pressure and changes in metabolism (see insulin- above).</p> <p>TCDs are often normal in patients who appear brain-dead by exam.</p> |
| <b>HD 7</b>   | Survival is associated with detection of neutralizing antibody by HD 7 |                                                                                                                                                                                                                 | <p><u>Key test timing:</u> Serum and CSF for rabies neutralizing antibody (HD 7)</p> <p>Saliva for PCR</p> | Lack of detection of neutralizing antibody in CSF by HD 7 indicates medical futility of further care unless you are using an antiviral or other biological. This lab test is essential to unnecessary prolongation of medical care.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>HD 8</b>   | Risk of cardiac arrest abates (unless you use                          | Rapidly taper sedation                                                                                                                                                                                          |                                                                                                            | There is generally a “honeymoon” of medical stability between HD 8-12 that may be useful for tracheostomy and use of diuretics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |


Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)

|                  |                                                               |  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|------------------|---------------------------------------------------------------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | favipiravir or other biological)                              |  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>HD 10</b>     | Total paralysis by HD 10                                      |  | Saliva for PCR; serum and CSF for rabies neutralizing antibody (HD 10)                                                                                                                                                            | Paralysis reverses (distal to proximal) with virus clearance and often includes orofacial dyskinesias (myokymia) during progression and recovery. These are not seizures.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>HD 12-15</b>  | Severe generalized intracranial vasospasm; diabetes insipidus |  | Optional transcranial doppler ultrasound (needs baseline study)                                                                                                                                                                   | <u>In the absence of neutralizing antibody by HD 7</u> , the patient develops dysautonomia, drop in intracranial pressure and blood flow (high resistance), with flattening of EEG and pupillary dilation, followed in 24 hours by diabetes insipidus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>HD 15 -21</b> | Medical recovery (or criteria for futility)                   |  | Saliva for PCR; serum and CSF for rabies neutralizing antibody (HD 15 and weekly thereafter until stable)<br><br>Criteria for futility (HD >10): diabetes insipidus, isoelectric EEG, CSF lactate > 4 mM, CSF protein > 250 mg/dL | Following “type II” vasospasm, low resistance, chaotic blood flow then supervenes leading to cerebral edema and death. There is no recovery.<br><br><i>Virology studies should ALWAYS be completed even if the patient dies. This allows retrospective interpretation of care decisions and the opportunity to detect new complications and improve future care.</i><br><br>In the presence of CSF neutralizing antibody (>0.3 IU/ml in our experience), the patient regains pupillary activity, cough and diaphragmatic activity, and re-innervates distal to proximal motor reflexes, then function. Sensation and vestibular function lag. Myokimia re-appears. Dysautonomia occurs with cares and must be tolerated. There are a few days of profuse sialorrhea, bronchial and gastric secretions. There is a subtle SIADH. A few patients develop profound cachexia before recovering. The patients do not regulate temperature well and heart rate (and blood pressure) varies by body temperature; the patients require bundling. |
| Autopsy          |                                                               |  |                                                                                                                                                                                                                                   | There are many ICU complications that result in death during rabies care. The autopsy will identify new complications in 25% of patients. It may show virus clearance (evidenced by lack of virus cultivation and spotty rather than homogeneous detection of virus antigen and RNA in tissues). This finding of virus clearance is often of consolation to family members and the medical staff.<br><br>There are needle biopsy alternatives to standard autopsy when the standard form is prohibited by                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)


|  |  |  |  |                                                                                             |
|--|--|--|--|---------------------------------------------------------------------------------------------|
|  |  |  |  | cultural or religious norms. THERE HAS NEVER BEEN TRANSMISSION OF RABIES DURING AN AUTOPSY. |
|--|--|--|--|---------------------------------------------------------------------------------------------|

Figure 1. Immune response to insect bat rabies with vaccination in serum and CSF after partial post-exposure prophylaxis, vaccine failure, or vaccination when rabies is symptomatic from our series and the literature. (We have few of these, likely indicative of the lower burden of disease and the efficacy of PEP.) One of two patients had immune response detected by 7 days but did not survive; the other died at 7 days. Horizontal lines show antibody titers associated with survival and good neurological outcome.



## APPENDIX

Heart rate norms. There is always some tachycardia and fluctuation in rabies. We must tolerate some. By significant dysautonomia that we need to treat with sedation, we refer to heart rates and blood pressures above or below the 99<sup>th</sup> percentiles for age or height (e.g. P >150 or < 60; BPsyst>120 or < 75 in children. For adults, we refer to heart rates and blood pressures above or below the 95<sup>th</sup> percentiles -- for lack of more extreme normative data (e.g. BPsyst > 152 or < 100.



Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)

Blood pressure norms (adults)




Figure 1. Resting pulse rates for U.S. males, by age: National Health and Nutrition Examination Survey, 1999–2008




Figure 2. Resting pulse rates for females, by age: National Health and Nutrition Examination Survey, 1999–2008


# Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)

## Blood pressue norms (child)

**3 to 20 years: Boys**  
**BP-for-stature percentiles**

NAME \_\_\_\_\_


RECORD # \_\_\_\_\_



**3 to 20 years: Girls**  
**BP-for-stature percentiles**


NAME \_\_\_\_\_

RECORD # \_\_\_\_\_



SOURCE: American Pediatric and Adolescent Hypertension Task Force (1987), Task Force on Blood Pressure Control in Children (1987), and the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents (2004). Height-for-age percentiles for BP percentiles > 95th, unadjusted for BP percentiles > 95th, and median for BP percentiles > 95th, and median for BP percentiles > 95th.

Optic nerve sheath diameter norms (adult)



**Fig. 1.** Scatter Plot 1: ICP vs ONSD. Scatter plot of 75 measurements of ICP in the X axis against the ONSD value in the Y axis. Generally this scatter plot shows a linear relationship. However towards the extreme end of ICP value, the ONSD value started to reach a plateau phase. This is due to maximal dilatation of the optic nerve sheath despite elevation of ICP. Prior studies suggested that with increasing ICPs there might be a maximum nerve sheath diameter that would create an asymptotic relationship. A scatterplot of ICP as a function of ONSD demonstrates this relationship with the maximum ONSD in this population of 6.31 mm.

Optic nerve sheath diameter norms (child)

**Table 6** ONSD cut-off values in children >1 year old and children with a closed AF

| ICP threshold<br>(in mmHg) | ONSD cut-off in children<br>over 1 year old (in mm) | ONSD cut-off in children with<br>a closed AF (in mm) |
|----------------------------|-----------------------------------------------------|------------------------------------------------------|
| ≥20                        | 5.75                                                | 5.81                                                 |
| ≥15                        | 5.49                                                | 5.50                                                 |
| ≥10                        | 5.20                                                | 5.20                                                 |
| ≥5                         | 5.10                                                | 5.00                                                 |

Transcranial doppler ultrasound norms (child): mean flow (time-averaged mean max) and resistive index, middle cerebral artery

Table 3 Mean (SD) flow velocities in basal cerebral arteries (in cm/second) in a cross sectional study of healthy children (n=112)

| Age                                      | n  | Middle cerebral artery | Internal carotid artery | Anterior cerebral artery | Posterior cerebral artery |         | Basilar artery |
|------------------------------------------|----|------------------------|-------------------------|--------------------------|---------------------------|---------|----------------|
|                                          |    |                        |                         |                          | P1*                       | P2†     |                |
| <b>Systolic peak flow velocity:</b>      |    |                        |                         |                          |                           |         |                |
| 0-10 days                                | 18 | 46 (10)                | 47 (9)                  | 35 (8)                   | —                         | —       | —              |
| 11-90 days                               | 14 | 75 (15)                | 77 (19)                 | 58 (15)                  | —                         | —       | —              |
| 3-11.9 months                            | 13 | 114 (20)               | 104 (12)                | 77 (15)                  | —                         | —       | —              |
| 1-2.9 years                              | 9  | 124 (10)               | 118 (24)                | 81 (19)                  | 67 (18)                   | 69 (9)  | 71 (6)         |
| 3-5.9 years                              | 18 | 147 (17)               | 144 (19)                | 104 (22)                 | 84 (20)                   | 81 (16) | 88 (9)         |
| 6-9.9 years                              | 20 | 143 (13)               | 140 (14)                | 100 (20)                 | 82 (11)                   | 75 (10) | 85 (17)        |
| 10-18 years                              | 20 | 129 (17)               | 125 (18)                | 92 (19)                  | 75 (16)                   | 66 (10) | 68 (11)        |
| <b>Mean flow velocity‡:</b>              |    |                        |                         |                          |                           |         |                |
| 0-10 days                                | 18 | 24 (7)                 | 25 (6)                  | 19 (6)                   | —                         | —       | —              |
| 11-90 days                               | 14 | 42 (10)                | 43 (12)                 | 33 (11)                  | —                         | —       | —              |
| 3-11.9 months                            | 13 | 74 (14)                | 67 (10)                 | 50 (11)                  | —                         | —       | —              |
| 1-2.9 years                              | 9  | 85 (10)                | 81 (8)                  | 55 (13)                  | 50 (17)                   | 50 (12) | 51 (6)         |
| 3-5.9 years                              | 18 | 94 (10)                | 93 (9)                  | 71 (15)                  | 56 (13)                   | 48 (11) | 58 (6)         |
| 6-9.9 years                              | 20 | 97 (9)                 | 93 (9)                  | 65 (13)                  | 57 (9)                    | 51 (9)  | 58 (9)         |
| 10-18 years                              | 20 | 81 (11)                | 79 (12)                 | 56 (14)                  | 50 (10)                   | 45 (9)  | 46 (8)         |
| <b>End diastolic peak flow velocity:</b> |    |                        |                         |                          |                           |         |                |
| 0-10 days                                | 18 | 12 (7)                 | 12 (6)                  | 10 (6)                   | —                         | —       | —              |
| 11-90 days                               | 14 | 24 (8)                 | 24 (8)                  | 19 (9)                   | —                         | —       | —              |
| 3-11.9 months                            | 13 | 46 (9)                 | 40 (8)                  | 33 (7)                   | —                         | —       | —              |
| 1-2.9 years                              | 9  | 65 (11)                | 58 (5)                  | 40 (11)                  | 36 (13)                   | 35 (7)  | 35 (6)         |
| 3-5.9 years                              | 18 | 65 (9)                 | 66 (8)                  | 48 (9)                   | 40 (12)                   | 35 (9)  | 41 (5)         |
| 6-9.9 years                              | 20 | 72 (9)                 | 68 (10)                 | 51 (10)                  | 42 (7)                    | 38 (7)  | 44 (8)         |
| 10-18 years                              | 20 | 60 (8)                 | 59 (9)                  | 46 (11)                  | 39 (8)                    | 33 (7)  | 36 (7)         |

\*Precommunicating part of posterior cerebral artery.

†Postcommunicating part of posterior cerebral artery.

‡Mean flow velocity=time-mean of the maximal velocity envelope curve.

Table 3. Mean (SD) flow velocities in basal cerebral arteries (in cm/second) in a cross sectional study of healthy children (n=112). Mean reference values of

## 7. Appendices

115

**Appendix IVe. Resistance index RI = (vs—vd)/vs—mean values**

| Age     |        | MCA  | ICA   | SIPH | ACA               | PCA 1 | PCA 2 | BAS  |
|---------|--------|------|-------|------|-------------------|-------|-------|------|
| 0–10    | days   | 0.71 | 0.71* | —    | 0.64 <sup>+</sup> | —     | —     | —    |
| 11–90   | days   | 0.63 | 0.71* | —    | 0.60 <sup>+</sup> | —     | —     | —    |
| 3–11.9  | months | 0.58 | 0.67* | —    | 0.60 <sup>+</sup> | —     | —     | —    |
| 1–2.9   | years  | 0.47 | 0.52  | 0.57 | 0.55              | 0.55  | 0.52  | 0.55 |
| 3–5.9   | years  | 0.55 | 0.60  | 0.63 | 0.57              | 0.58  | 0.59  | 0.60 |
| 6–9.9   | years  | 0.50 | 0.55  | 0.55 | 0.57              | 0.55  | 0.52  | 0.55 |
| 10–16.9 | years  | 0.53 | 0.58  | 0.58 | 0.58              | 0.55  | 0.57  | 0.57 |

Standard deviations:

|               |   |           |
|---------------|---|-----------|
| 0–10 days     | : | 0.11      |
| 11–90 days    | : | 0.07–0.10 |
| 3–11.9 months | : | 0.05–0.07 |
| > 1 year      | : | 0.04–0.06 |

Milwaukee Protocol, version 7.1 F (insect bat rabies, vaccinated)

Transcranial doppler ultrasound norms (adult)

| <b>TABLE 1 Normal Reference Values of Blood Flow Velocities in the Basal Cerebral Arteries in Different Age Groups</b> |          |              |                 |                 |               |
|------------------------------------------------------------------------------------------------------------------------|----------|--------------|-----------------|-----------------|---------------|
| Blood Flow Velocity (cm/sec)                                                                                           | <i>n</i> | Subjects     |                 |                 |               |
|                                                                                                                        |          | All          | 20–40 Years Old | 41–60 Years Old | >60 Years Old |
| ACA                                                                                                                    | 313      |              |                 |                 |               |
| Peak                                                                                                                   |          | 79 (37–121)  | 82 (40–124)     | 80 (36–124)     | 72 (52–102)   |
| Mean                                                                                                                   |          | 53 (33–83)   | 56 (42–84)      | 53 (37–85)      | 44 (22–66)    |
| End-diastolic                                                                                                          |          | 35 (13–57)   | 38 (16–60)      | 35 (13–57)      | 28 (12–44)    |
| MCA                                                                                                                    | 335      |              |                 |                 |               |
| Peak                                                                                                                   |          | 110 (54–166) | 120 (64–176)    | 109 (65–175)    | 92 (58–126)   |
| Mean                                                                                                                   |          | 73 (33–133)  | 81 (41–121)     | 73 (35–111)     | 59 (37–81)    |
| End-diastolic                                                                                                          |          | 49 (21–77)   | 55 (29–81)      | 49 (23–75)      | 37 (21–53)    |
| PCA                                                                                                                    | 336      |              |                 |                 |               |
| Peak                                                                                                                   |          | 71 (39–103)  | 75 (43–107)     | 74 (40–108)     | 62 (38–86)    |
| Mean                                                                                                                   |          | 49 (25–73)   | 52 (28–76)      | 51 (25–75)      | 40 (22–58)    |
| End-diastolic                                                                                                          |          | 33 (15–51)   | 36 (20–52)      | 34 (18–50)      | 26 (14–38)    |

ACA = anterior cerebral artery, MCA = middle cerebral artery, PCA = posterior cerebral artery. Range of velocities (calculated as mean  $\pm$  2 SD) is given in parentheses.

| <b>TABLE 2 Normal Reference Values of Impedance Indexes in the Basal Cerebral Arteries in Different Age Groups</b> |                 |                 |                 |                 |
|--------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Impedance Index <sup>a</sup>                                                                                       | Subjects        |                 |                 |                 |
|                                                                                                                    | All             | 20–40 Years Old | 41–60 Years Old | >60 Years Old   |
| ACA                                                                                                                |                 |                 |                 |                 |
| PI                                                                                                                 | 0.87 $\pm$ 0.16 | 0.80 $\pm$ 0.14 | 0.85 $\pm$ 0.16 | 1.02 $\pm$ 0.18 |
| RI                                                                                                                 | 0.56 $\pm$ 0.07 | 0.53 $\pm$ 0.05 | 0.56 $\pm$ 0.07 | 0.62 $\pm$ 0.06 |
| MCA                                                                                                                |                 |                 |                 |                 |
| PI                                                                                                                 | 0.86 $\pm$ 0.15 | 0.83 $\pm$ 0.14 | 0.82 $\pm$ 0.13 | 0.96 $\pm$ 0.17 |
| RI                                                                                                                 | 0.56 $\pm$ 0.06 | 0.54 $\pm$ 0.05 | 0.55 $\pm$ 0.05 | 0.60 $\pm$ 0.06 |
| PCA                                                                                                                |                 |                 |                 |                 |
| PI                                                                                                                 | 0.81 $\pm$ 0.15 | 0.76 $\pm$ 0.12 | 0.79 $\pm$ 0.12 | 0.94 $\pm$ 0.16 |
| RI                                                                                                                 | 0.54 $\pm$ 0.07 | 0.52 $\pm$ 0.06 | 0.53 $\pm$ 0.05 | 0.60 $\pm$ 0.09 |

ACA = anterior cerebral artery, PI = pulsatility index, RI = resistivity index, MCA = middle cerebral artery, PCA = posterior cerebral artery.

<sup>a</sup>Mean  $\pm$  2 SD.